Healthcare
Genfit S.A.(GNFTF)
Live Price
Offline$9.98
+0.00% today
1Y Change
+181.92%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $400.00M
- Revenue Growth
- -2.4%
- EPS Growth
- -5866.7%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genfit S.A. (GNFTF) is a Healthcare stock with a market cap of $400.00M and listed on OTC. The stock last traded around $9.98 and up 181.9% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -2.4%, EPS growth of -5866.7%, a dividend yield of 0.0%. What stands out right now is revenue -2.4%, EPS -5866.7%, free cash flow -287.8% with operating margin -84.3% and ROIC -41.4%. Valuation sits in the middle of the pack at price/sales 6.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GNFTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-2.4% vs +7.6% peer median
Operating Margin
Below sector median
-84.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Apr 2, 2026 with revenue ahead of estimates by 0.0%.
The operating picture looks softer than before
Revenue is at -2.4% and EPS is at -5866.7%, with operating margin around -84.3%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 29, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 2, 2026 | +0.0% | +0.0% | +0.0% | -9.2% |
2025 May 22, 2025 | โ | +0.0% | +0.0% | -7.3% |
2025 Apr 24, 2025 | -138.3% | +0.0% | +0.0% | -7.3% |
Benchmark Edge
GNFTF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GNFTF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GNFTF Max Drawdown
-25.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GNFTF and SPY.
Company Overview
Genfit S.A.
Other OTC
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
- Leadership
- Pascal Prigent
- IPO Date
- Jan 27, 2014
- Employees
- 180
- Street Address
- Parc EurasantE
- Mailing
- Loos, 59120
- Region
- Loos, FR
- Reporting Currency
- USD
- Investor Line
- 33 3 20 16 40 00
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.0
- Price/Book
- โ
Growth
- Revenue
- -2.4%
- EPS
- -5866.7%
- Free Cash Flow
- -287.8%
Profitability
- Gross Margin
- 26.0%
- Operating Margin
- -84.3%
- Net Margin
- -127.4%
- ROE
- -596.4%
- ROIC
- -41.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.00
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.